AmycretinvsMariTide

Amycretin is a unimolecular co-agonist that simultaneously activates both the GLP-1 receptor and the amylin (AMY) receptor — the first peptide engineered to combine these two complementary satiety pathways in a single molecule rather than as a two-drug combination. The design philosophy is to deliver the additive weight-loss benefit demonstrated by CagriSema (semaglutide + cagrilintide) without the manufacturing, dosing, and patient-acceptance complexities of co-formulating two separate drugs.

The GLP-1 component drives appetite suppression centrally through hypothalamic POMC/CART activation and NPY/AgRP inhibition, slows gastric emptying via vagal signalling, and stimulates glucose-dependent insulin secretion from pancreatic beta cells. The amylin component activates calcitonin-receptor/RAMP heterodimer complexes concentrated in the area postrema and nucleus tractus solitarius — brainstem regions outside the blood-brain barrier that form a parallel satiety circuit reducing meal size and food-seeking behaviour through neuroanatomically distinct pathways.

Because GLP-1 and amylin signal through different receptor families and target different neurons in the appetite control network, their effects are additive rather than redundant. Phase 1b/2a data showed up to 22% body weight reduction at 36 weeks for the subcutaneous form — comparable to CagriSema with a simpler one-molecule profile. A particularly notable feature is the parallel development of an oral formulation, which would be the first oral peptide combination therapy for obesity if approved. Novo Nordisk's branded development name is zenagamtide, and the molecule is positioned as the company's strategic answer to retatrutide and tirzepatide.

MariTide (maridebart cafraglutide) is a peptide-antibody conjugate combining a GLP-1 receptor agonist peptide with a GIP receptor antagonist antibody. This dual GLP-1 agonist + GIP antagonist mechanism is distinctive — most competing dual incretin drugs (tirzepatide, CT-388, VK2735) activate both receptors. The rationale for GIP antagonism is based on genetic and pharmacological evidence that loss-of-function in GIP signalling is associated with reduced obesity, suggesting that blocking rather than activating GIP may produce superior weight-loss outcomes.

The GLP-1 agonist component drives the established appetite-suppression and glycemic-control effects of the incretin pathway. The GIP receptor antagonist antibody simultaneously blocks GIP signalling at adipocytes and centrally, which preclinical data suggest enhances energy expenditure, reduces lipid storage, and amplifies the weight-loss effect of GLP-1 receptor activation. Whether GIP agonism (as in tirzepatide) or GIP antagonism (as in MariTide) is superior remains an open question that Phase 3 head-to-head data may eventually resolve.

The antibody-conjugated structure produces an exceptional pharmacokinetic profile, with a half-life of approximately three weeks. This supports once-monthly subcutaneous dosing — a unique practical advantage over the once-weekly schedules of all other late-stage obesity drugs. Phase 2 results showed roughly 20% body weight loss at 52 weeks. Animal studies have also suggested slower weight regain after discontinuation than seen with shorter-acting GLP-1 agonists, possibly due to the prolonged drug exposure during the washout period. Phase 3 MARITIME trials launched in 2026 will define the molecule's clinical positioning.